EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sudapyridine (WX-081) inhibits Mycobacterium tuberculosis by targeting ATP synthase and upregulating host innate immunity

Xinda Li iD, Xiaoyi Luo, Bin Wang, Lei Fu, Xi Chen, Yu Lu iD

mSphere · 2025

DOI: 10.1128/msphere.00149-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mSphere, 2025. Verfasst von Xinda Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Beijing Chest Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Immunity, Innate, Antitubercular Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Municipal Administration of Hospitals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug-resistant tuberculosis (DR-TB) urgently requires safer, more accessible alternatives to bedaquiline (BDQ), which faces critical flaws like cardiotoxicity, high costs, and emerging resistance. WX-081, a promising BDQ alternative, has demonstrated superior anti-TB activity and improved safety in clinical studies. However, its mechanism of action remains unexplored, underscoring the need for further research to optimize its potential in advancing global TB elimination efforts. This study reveals WX-081’s dual mechanisms: targeting atpE to disrupt ATP synthase and proton motive force via resistance screening, gene sequencing, and functional assays while enhancing host immunity through macrophage transcriptomics. Molecular docking confirmed atpE binding sites, and immune activation pathways (NF-κB/MAPK) were identified, positioning WX-081 as a potent, safe anti-DR-TB candidate despite unresolved mechanistic details. IMPORTANCE Bedaquiline, a key drug for drug-resistant tuberculosis, is restricted by safety issues impacting its clinical utility. Its next-generation alternative, WX-081, has advanced to Phase III trials but lacks in-depth studies on its mechanism and host immune-modulatory effects, necessitating further research before broad clinical adoption.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisImmunity, InnateAntitubercular AgentsHumansMacrophagesMolecular Docking SimulationMiceAnimalsUp-RegulationTuberculosis, Multidrug-ResistantDiarylquinolinesPyridines

Stichwörter der Autor:innen

ATP synthaseWX-081drug-resistant tuberculosisimmunomodulation

Substanzen

Antitubercular AgentsDiarylquinolinessudapyridinePyridines

Autor:innen und Institutionen

  • Department of Pharmacology, Beijing Chest Hospital, Capital Medical University, Beijing, China.
  • Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.

ORCID-Profile: Xinda Li, Yu Lu

Förderung

  • National Natural Science Foundation of China
  • Beijing Municipal Administration of Hospitals

Zitieren

APA

Li, X., Luo, X., Wang, B., Fu, L., Chen, X., & Lu, Y. (2025). Sudapyridine (WX-081) inhibits Mycobacterium tuberculosis by targeting ATP synthase and upregulating host innate immunity. mSphere. https://doi.org/10.1128/msphere.00149-25

Vancouver

Li X, Luo X, Wang B, Fu L, Chen X, Lu Y. Sudapyridine (WX-081) inhibits Mycobacterium tuberculosis by targeting ATP synthase and upregulating host innate immunity. mSphere. 2025. doi:10.1128/msphere.00149-25

BibTeX
@article{Li2025,
  author = {Li, Xinda and Luo, Xiaoyi and Wang, Bin and Fu, Lei and Chen, Xi and Lu, Yu},
  title = {Sudapyridine (WX-081) inhibits Mycobacterium tuberculosis by targeting ATP synthase and upregulating host innate immunity},
  journal = {mSphere},
  year = {2025},
  doi = {10.1128/msphere.00149-25}
}
Kostenlos starten →